Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2022 Mar;101(3):491-511.
doi: 10.1007/s00277-021-04746-y. Epub 2022 Jan 7.

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

Larissa Henze  1 , Christoph Buhl  2 , Michael Sandherr  3 , Oliver A Cornely  4   5   6   7 , Werner J Heinz  8 , Yascha Khodamoradi  9 , Til Ramon Kiderlen  10   11   12 , Philipp Koehler  4   5   7 , Alrun Seidler  13 , Rosanne Sprute  4   5   6   7 , Martin Schmidt-Hieber  14 , Marie von Lilienfeld-Toal  15   16
Affiliations
Practice Guideline

Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus

Larissa Henze et al. Ann Hematol. 2022 Mar.

Abstract

Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among patients with malignancies and manifest particularly as herpes simplex stomatitis in patients with acute leukaemia treated with intensive chemotherapy and as herpes zoster in patients with lymphoma or multiple myeloma. In recent years, knowledge on reactivation rates and clinical manifestations has increased for conventional chemotherapeutics as well as for many new antineoplastic agents. This guideline summarizes current evidence on herpesvirus reactivation in patients with solid tumours and hematological malignancies not undergoing allogeneic or autologous hematopoietic stem cell transplantation or other cellular therapy including diagnostic, prophylactic, and therapeutic aspects. Particularly, strategies of risk adapted pharmacological prophylaxis and vaccination are outlined for different patient groups. This guideline updates the guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) from 2015 "Antiviral prophylaxis in patients with solid tumours and haematological malignancies" focusing on herpes simplex virus and varicella zoster virus.

Keywords: Acyclovir; Antiviral prophylaxis; Hematologic malignancies; Herpes stomatitis; Herpes zoster; Solid tumours.

PubMed Disclaimer

Conflict of interest statement

Larissa Henze (LH):

Financing of Scientific Research: German Federal Ministry of Research and Education (BMBF).

Outside the submitted work.

Christoph Buhl (CB):

CB has no financial or non-financial interests to disclose.

Michael Sandherr (MS):

Honoraria: Roche, Bristol-Myers Squibb, Novartis.

Oliver A. Cornely (OAC):

OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, PSI, Scynexis, Seres; Honoraria for lectures from Abbott, Al-Jazeera Pharmaceuticals, Astellas, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Pfizer; Payment for expert testimony from Cidara; Participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Jannsen, MedPace, Paratek, PSI, Shionogi; A pending patent currently reviewed at the German Patent and Trade Mark Office; Other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley.

Werner J. Heinz (WJH):

Financing of scientific research: MSD Sharp & Dohme/Merck and Pfizer;

Other Financial Relationships: serves on the speakers’ bureaus of Abbvie, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, Janssen, MSD Sharp & Dohme, and Pfizer; received travel grants from Abbvie, Alexion, Astellas, Lilly, MSD Sharp & Dohme, Novartis and Pfizer.

Yascha Khodamoradi (YK):

Other Financial Relationships: speaker’s fee and travel grant from GILEAD Science, MSD Sharp & Dome.

Til Ramon Kiderlen (TRK):

Advisory Role: GSK.

Honoraria: Pfizer, GSK.

Financing of scientific research: Pfizer.

Philipp Koehler (PK):

Advisory Role and/or Honoraria: Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, MSD Sharp & Dohme GmbH, Noxxon N.V., University Hospital, LMU Munich;

Financing of scientific research: German Federal Ministry of Research and Education and the State of North Rhine-Westphalia, Germany;

Non-financial scientific grants: Miltenyi Biotec GmbH, Bergisch Gladbach, Germany, the Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany.

Outside the submitted work.

Alrun Seidler (AS):

AS has no financial or non-financial interests to disclose.

Rosanne Sprute (RS):

RS has no financial or non-financial interests to disclose.

Martin Schmidt-Hieber (MSH):

Advisory Role or Expert Testimony (no personal fee): Celgene GmbH, Amgen, Kite/Pharma Gilead, Sanofi;

Other Financial Relationships: financial support of educational meetings at the Carl-Thiem-Klinikum Cottbus by Janssen-Cilag GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Novartis Pharma Oncology, Pfizer Pharma GmbH, Roche Pharma AG, Vifor Pharma Deutschland

GmbH, Celgene GmbH.

Marie von Lilienfeld-Toal (MvL):

Advisory Role or Expert Testimony: Celgene, Gilead, Oncopeptides, MSD, 4DPharma, Janssen, Shionogi, Pfizer.

Honoraria: Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Abbvie, AstraZeneca, Pfizer.

Financing of Scientific Research: German Federal Ministry of Research and Education, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, DFG (German Research Foundation), Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides.

Other Financial Relationships (travel grants): Janssen, Celgene.

References

    1. Chen S-Y, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–334. doi: 10.1007/s15010-013-0550-8. - DOI - PMC - PubMed
    1. Ruiz-Camps I, Aguilar-Company J. Risk of infection associated with targeted therapies for solid organ and hematological malignancies. Ther Adv Infect Dis. 2021;8:2049936121989548. doi: 10.1177/2049936121989548. - DOI - PMC - PubMed
    1. Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer. 2016;67:21–37. doi: 10.1016/j.ejca.2016.07.025. - DOI - PubMed
    1. Lee HS, Park JY, Shin SH, Kim SB, Lee JS, Lee A, et al. Herpesviridae viral infections after chemotherapy without antiviral prophylaxis in patients with malignant lymphoma: incidence and risk factors. Am J Clin Oncol. 2012;35(2):146–150. doi: 10.1097/COC.0b013e318209aa41. - DOI - PubMed
    1. Tan IL, McArthur JC, Venkatesan A, Nath A. Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology. 2012;79(21):2125–2132. doi: 10.1212/WNL.0b013e3182752ceb. - DOI - PMC - PubMed

Publication types

MeSH terms